CSL and more blue-chip ASX 200 bargains I'd buy before 2026

Here's why I think these shares could be cheap buys before the end of the year.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • CSL's recent share price dip, driven by factors like slower margin recovery and external uncertainties, presents a rare buying opportunity due to its enduring strengths in plasma, R&D, and specialty medicines that position it well for long-term growth.
  • Macquarie's diversified financial prowess across asset management, banking, and commodities makes its current lower valuation appealing, as its adaptable business model is geared for sustained growth amid economic fluctuations and strategic investments.
  • Despite current challenges, Woolworths stands as an attractive large-cap opportunity with its resilient business model in essentials spending, expanding digital initiatives, and potential margin recovery, making it a compelling buy at its current discounted share price.

The ASX has spent most of 2025 swinging between optimism and anxiety, with inflation scares, rate hike speculation, and an AI-driven tech wobble keeping investors on edge.

But beneath is a rare opportunity to buy several high-quality ASX 200 blue chip shares at meaningful discounts.

Here are three bargains I'd be buying today.

A smiling woman holds a Facebook like sign above her head.

Image source: Getty Images

CSL Ltd (ASX: CSL)

CSL is rarely cheap. For most of the last decade, the biotech giant traded at a premium thanks to its global leadership in plasma therapies, vaccines, and emerging specialty medicines. But 2025 has been an unusually bumpy year. Slower margin recovery at CSL Behring, uncertainty around the Seqirus spin-off, falling influenza vaccine rates, and concerns about potential US tariff impacts have pushed its share price down by over a third.

What hasn't changed is the company's long-term earnings power. Plasma collection volumes are rising, CSL's R&D engine remains strong, and its therapy pipeline is expanding.

Trading on a valuation rarely seen for CSL, for long-term investors this could be a buying opportunity that doesn't come around very often.

Macquarie Group Ltd (ASX: MQG)

Macquarie's reputation as Australia's financial powerhouse wasn't built on smooth economic cycles. It was built through the company's ability to generate growing profits whatever the market throws at it.

That's why the current weakness in its share price, is looking like an opportunity. Macquarie has four engines: asset management, banking, commodities, and investment banking. When one slows, another usually accelerates. The company has also positioned itself for the next decade through investments in renewables, digital infrastructure, and global energy transition assets.

For investors with patience, buying Macquarie during periods of temporary earnings softness has historically paid off handsomely. I believe the same could happen for investors buying at today's levels.

Woolworths Group Ltd (ASX: WOW)

Finally, I think Woolworths has quietly become one of the more attractive large-cap opportunities on the ASX after a challenging 12 months. The retailer has been under pressure due to consumers trading down, competition from Coles Group Ltd (ASX: COL), and higher operating costs. But these headwinds are cyclical, not structural.

Woolworths still owns one of the most defensible business models in the country. Food and essentials spending remain remarkably resilient, and it continues to grow its digital footprint, loyalty program, and supply-chain efficiencies.

So, with the share price sitting well below its 52-week high and margins set to recover as cost pressures ease, Woolworths could be a top blue chip pick in the current market.

Motley Fool contributor James Mickleboro has positions in CSL and Woolworths Group. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group and Woolworths Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Blue Chip Shares

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Blue Chip Shares

Where I'd invest $5,000 in ASX blue-chip shares

Some blue chips stand still. Others keep improving. These are the ones I’d be watching.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Blue Chip Shares

3 ASX shares I'd feel comfortable holding for the next decade

I think that over a decade, consistency and adaptability can matter more than short-term performance.

Read more »

Happy man at an ATM.
Blue Chip Shares

3 ASX 200 blue chip shares to buy with $20,000

Let's see why these leading shares could be worth considering this month.

Read more »

Happy man holding Australian dollar notes, representing dividends.
Blue Chip Shares

2 ASX blue-chip shares offering big dividend yields

These businesses can provide investors with good passive income.

Read more »

Person holding a blue chip.
Blue Chip Shares

2 ASX 200 blue-chip shares worth owning in April 2026

Is this a great time to invest in these shares?

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Blue Chip Shares

Better buy? CSL vs Rio Tinto shares

When two quality shares diverge, I think it is worth taking a closer look.

Read more »

A man looking at his laptop and thinking.
Blue Chip Shares

These ASX blue chips now look too cheap to ignore

These blue chips could be worth a closer look after sharp declines.

Read more »

Young woman thinking with laptop open.
Blue Chip Shares

Why is everyone selling Wesfarmers shares?

It looks like the retail conglomerate fell out of favour with investors this year.

Read more »